Netsmart expands board of directors

Netsmart Technologies has added Carl Byers to its board of directors. Byers is a venture partner at Fidelity Biosciences, a unit of Fidelity Investments. Netsmart is a provider of clinical and business software solutions for health and human services organizations.

Coherus BioSciences nabs $55 mln Series C

Coherus BioSciences has raised $55 million in Series C funding. The investors included KKR, Venrock, RA Capital Management, Rock Springs Capital, Fidelity Biosciences, Sofinnova Ventures, Lilly Ventures and Vivo Capital. Based in Redwood City, Calif., Coherus BioSciences is a biologics platform focused on biosimilars.

Cureatr expands board of directors with new addition

Cureatr, a mobile care coordination solution for healthcare providers, has added Carl Byers to its board of directors. The appointment is effective immediately. Byers is a venture partner at Fidelity Biosciences, a VC fund. Cureatr’s backers include Cardinal Partners, Milestone Venture Partners, JMI Services and the Partnership Fund for New York City.


Digital health company Wellframe scores $1.5 mln seed funds

Wellframe has closed $1.5 million in seed funding. The investors included athenahealth CEO Jonathan Bush; Tim Draper, founder and managing director of Draper Fisher Jurvetson; Carl Byers, venture partner at Fidelity Biosciences; and James Nahirny, founder and manager partner at Leerink Capital Partners. Based in Boston, Wellframe is a digital health firm.

Acacia Pharma Secures Series B

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, has raised 15 million pounds ($23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures also participated in the round.

ViewRay Raises Fresh $15M for Its Medical Imaging Technology

ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company’s machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay’s investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.

Phizer Buys VC-Backed NextWave Pharmaceuticals

Phizer is snapping up NextWave Pharmaceuticals—a company backed by a laundry list of investors including Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures. Under the terms of the deal, Pfizer will pay $255 million to NextWave’s shareholders at closing. NextWave’s shareholders are eligible to receive up to $425 million in additional money, based on sales milestones. NextWave closed a $45 million round last January.

AxioMed Closes Series D Financing

AxioMed Spine Corporation, a spinal orthopedics company has closed its Series D financing, raising $5 million in two tranches from current and new investors. This funding boosts the previously announced $15 million Series D financing. Investors in the business include Siemens Venture Capital, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors. PRESS RELEASE […]

Liazon Secures Inks $18.2m for Expansion and New Products

Liazon, a private health benefits exchange, has closed $18.2 million in new funding to expand nationwide and develop new products. Bessemer Venture Partners and Fidelity Biosciences led the round with follow-on funding from existing investors Bain Capital Ventures and Rand Capital, SBIC. Founded in 2007, Liazon has offices in Buffalo, N.Y., New York City and […]

Slideshow: Where the Biotech & Device Investors Are–Q4 Edition

Lately, there’s been a whole lot of bemoaning of this and that to explain why VCs are abandoning the biotech and device space and why strategics are slowing early-stage funding. Lawmakers and regulators have made it too tough to IPO. Lawmakers and regulators have made it too tough to get anything approved at the FDA. […]

Allergan Buys Vicept Therapeutics

Allergan is buying privately held dermatology company Vicept Therapeutics. Formed in 2009, Vicept is backed by investors including Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Under the terms of the acquisition, which is expected to close during the third quarter, Allergan will pay $75 million in cash up-front, as well as up to $200 million in payments tied to specific milestones.

CFO Splits Globespan as Zynga IPO Looms

Globespan Capital Partners CFO Mary Bevelock Pendergast has left the venture capital firm to take the same role at Fidelity Biosciences, peHUB has learned.

Fidelity Biosciences’s site states she has worked there as CFO since April 2011, yet, as of this afternoon, her bio page at Globespan remained operational.

ED NOTE: Nope, now it’s down.

Judging by Globespan’s description of her, Pendergast will leave a void behind in her wake. She managed all finance and administrative functions of the firm…

Ultragenyx Seals $45M Series A

One-year-old start-up Ultragenyx Pharmaceutical Inc. has closed on a whopping $45 million Series A round co-led by TPG Biotech and Fidelity Biosciences. Other investors include HealthCap and Pappas Ventures. The money will help Novato, Calif.-based Ultragenyx continue development of its rare disease therapeutics. As a result of the round, Eran Nadav of TPG Biotech; Ben Auspitz of Fidelity Biosciences; and Mårten Steen of HealthCap will join the company’s board.

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget